✦ LIBER ✦

P-573 Docetaxel-innotecan doublet chemotherapy as first-line therapy for advanced non-small cell lung cancer: A Phase II study

✍ Scribed by Shamseddine, A.; Abou-Mourad, Y.; Makarem, J.; Kattan, J.; Farhat, F.; Jalloul, R.; Mukaddem, W.; Taher, A.; Chehal, A.; Ghosen, M.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gemcitabine plus docetaxel as first-line

✍ Joaquín Casal; Margarita Amenedo; José Ramón Mel; Luis Miguel Antón; Rubén Rodrí 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 343 KB

Phase II study of gemcitabine plus oxali

✍ Cappuzzo, F; Novello, S; De Marinis, F; Franciosi, V; Maur, M; Ceribelli, A; Lor 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 117 KB

Gemcitabine and vinorelbine as first-lin

✍ E Laack; T Mende; J Benk; A Chemaissani; J Scholtze; C Lorenz; A Niestroy; K Dal 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 144 KB

Phase II trial of weekly docetaxel and g

✍ Sujith Kalmadi; Giles McNeill; Mellar Davis; David Peereboom; David Adelstein; T 📂 Article 📅 2006 🏛 Springer US 🌐 English ⚖ 68 KB

Phase II study of Docetaxel and Cisplati

✍ Pawel, J.v.; Faderl, B.; Wagner, H.; Krauβ, C.; Achterrath, W. 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 90 KB

Phase II study of exatecan mesylate (DX-

✍ Braybrooke, J.P; Ranson, M; Manegold, C; Mattson, K; Thatcher, N; Cheverton, P; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 165 KB